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After more than 50 years of intensive research and development, only one malaria vaccine
candidate, “RTS,S,” has progressed to Phase 3 clinical trials. Despite only partial efficacy,
this candidate is now forecast to become the first licensed malaria vaccine. Hence, more
efficacious second-generation malaria vaccines that can significantly reduce transmission
are urgently needed. This review will focus on a major obstacle hindering development
of effective malaria vaccines: parasite antigenic diversity. Despite extensive genetic diver-
sity in leading candidate antigens, vaccines have been and continue to be formulated
using recombinant antigens representing only one or two strains. These vaccine strains
represent only a small fraction of the diversity circulating in natural parasite populations,
leading to escape of non-vaccine strains and challenging investigators’ abilities to measure
strain-specific efficacy in vaccine trials. Novel strategies are needed to overcome antigenic
diversity in order for vaccine development to succeed. Many studies have now cataloged
the global diversity of leading Plasmodium falciparum and Plasmodium vivax vaccine anti-
gens. In this review, we describe how population genetic approaches can be applied to
this rich data source to predict the alleles that best represent antigenic diversity, polymor-
phisms that contribute to it, and to identify key polymorphisms associated with antigenic
escape. We also suggest an approach to summarize the known global diversity of a given
antigen to predict antigenic diversity, how to select variants that best represent the strains
circulating in natural parasite populations and how to investigate the strain-specific efficacy
of vaccine trials. Use of these strategies in the design and monitoring of vaccine trials will
not only shed light on the contribution of genetic diversity to the antigenic diversity of
malaria, but will also maximize the potential of future malaria vaccine candidates.
Keywords: Plasmodium falciparum, Plasmodium vivax, malaria, vaccine, strain, diversity, polymorphism, clinical
trials
INTRODUCTION
Malaria is the most devastating parasitic disease afflicting
humankind. The disease results from infection with protozoan
parasites of the genus, Plasmodium and is transmitted by female
anophelene mosquitoes. Of the 3.4 billion people in 108 coun-
tries at risk of malaria, 1.2 billion are at high risk of disease. In
2012, it was estimated that this disease caused 2000 deaths per day,
the majority (77%) being children <5 years of age in sub-Saharan
Africa infected with Plasmodium falciparum, the most virulent of
the five known human malaria parasites (1, 2). In addition to this
enormous heath toll, malaria exerts a heavy economic burden con-
tributing to the cycle of poverty in many resource-limited settings
(3). Although less lethal than P. falciparum, the majority of malaria
infections occurring outside of sub-Saharan Africa are caused by
Plasmodium vivax, with as many as 2.3 billion people at risk of
infection (4). Several unique features of P. vivax biology, includ-
ing its dormant stage in the human liver, make it more resistant
to malaria elimination. As a result, P. vivax is predicted to present
the ultimate obstacle to malaria elimination in endemic countries
(5). Nevertheless, research into this parasite lags far behind that of
P. falciparum due to its relatively recent recognition as a serious
threat to global public health and lack of a viable long term in vitro
culture system (4, 6).
Intensified malaria control efforts, supported by the Roll Back
Malaria campaign, have resulted in a 42% decrease in malaria
deaths worldwide in the last decade and many previously endemic
countries have now shifted from controlling malaria to an elimi-
nation agenda (1). In 2007, encouraged by the stunning impact of
this campaign, major funding bodies united to issue the ultimate
challenge, to eradicate malaria globally by progressive malaria
elimination from different countries and regions (3, 7). From
past malaria eradication attempts, it is clear that in order for
this ambitious goal to be achieved, malaria transmission must
be permanently interrupted. Interventions that reduce the para-
site reservoir, limit the rate at which infections are spread and the
duration of time that a human or mosquito host is infectious are
therefore urgently needed (8). In concert with other malaria con-
trol interventions, this could be achieved with the development of
a broadly effective malaria vaccine.
Malaria parasites are ancient organisms with abundant genetic
polymorphisms, much of which have evolved to escape host
immune responses and thus presents a major obstacle to the
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Box 1 Glossary of terms.
Strain: a parasite variant that is genetically unique and induces specific immune responses against one or more of its antigens.
Isolate: a parasite specimen derived from an infected individual that has been either adapted for in vitro culture or used directly for experi-
ments. Different isolates from the same population may contain parasites that are genetically identical at one or more loci. Individual isolates
may also contain one or more genetically distinct parasites if they have been collected from an individual with multiple infections.
Clone: a genetically homogeneous parasite isolate.
Polymorphism: variation in the population at a particular nucleotide or amino acid residue.
Allele: one variant of a particular genetic locus. It can refer to individual polymorphic sites within a nucleotide or amino acid sequence, or
the combination of all polymorphic sites in a gene or gene region (known as the haplotype).
Haplotype: a combination of alleles in a gene or gene region carried by a particular parasite clone.
Serotype: a haplotype from a gene or gene region that is antigenically unique and induces strain-specific responses.
Monovalent vaccine: a vaccine containing only one distinct antigen or one allele of the same antigen.
Multivalent vaccine: a vaccine containing two or more distinct antigens, or two or more alleles of the same antigen.
development of a vaccine that provides broad protection against
all, or at least the majority of strains (9). As with other pathogens,
the challenge in developing an effective malaria vaccine will be
to differentiate between diversity that is associated with immune
escape and cross protection, and that which has no bearing on the
immune response, having simply accumulated over time through
genetic drift or through adaptation to diverse host environments
(9). To date, the polymorphisms in malaria antigens targeted by
functionally important antibodies remain poorly characterized
(10). Very little is known of how sequence polymorphisms relate
to antigenic diversity or the potential for polymorphisms to medi-
ate vaccine escape for Plasmodium spp. (11). The key to success
with other pathogens has been the identification of immunolog-
ically relevant diversity. This has been achieved by performing
population genetic and structural studies to identify functionally
relevant polymorphisms, followed by molecular epidemiological
surveys or in vitro functional studies prior to development and
testing of vaccines (9). Narrowing the focus to immunologically
relevant polymorphisms would greatly reduce the diversity that
must be considered when developing multivalent malaria vaccines
covering a broad range of strains (2, 9, 12) (Box 1).
MALARIA VACCINES: PAST, PRESENT, AND FUTURE
A long lasting, broadly efficacious malaria vaccine would be the
most sustainable approach to control and eventually eradicate
malaria. That a malaria vaccine may be feasible is strongly sup-
ported by the fact that people living in malaria endemic areas
develop protective immunity against malaria symptoms during
childhood (13). By adulthood, decreases in the prevalence of infec-
tion and density of parasitemia are achieved indicating that this
immunity eventually provides some protection against infection
(14, 15). Passive transfer of immunoglobulin from hyper-immune
African adults to non-immune children with severe malaria was
shown to have curative properties, demonstrating that antibody
responses are largely responsible for protection against clinical dis-
ease (16). Furthermore, vaccination of rodent and primate models
with recombinant parasite antigens elicits high antibody titers
that are associated with protection against subsequent malaria
challenge (17–20). Although the development of malaria vaccines
has been an active focus of the malaria research community over
the last 50 years, a vaccine remains a missing component of malaria
control and elimination strategies (21).
Despite numerous promising malaria vaccine candidates and
several partially successful malaria vaccine trials (22–25), short-
lived protection, limited funding, and a lack of key technologies
has hampered further testing and the scale-up of clinical trials of
novel malaria vaccine candidates. The first successful malaria vac-
cine trial, based on a “whole parasite” approach, was conducted
in humans in the 1950s. Vaccination with irradiated sporozoites
was shown to protect against both homologous and heterologous
challenge in humans (26, 27). However, the need for large-scale
production prevented further development of this approach. With
the advent of molecular technologies in the 1980s, the focus shifted
to so-called “subunit” approaches, including highly immunogenic
parasite antigens as targets such as the circumsporozoite protein
(CSP), which was identified as the parasite antigenic determinant
targeted by immune responses induced by the sporozoite vaccine
(28). Following these early studies, and on the back of highly
promising pre-clinical studies, many small-scale subunit vaccine
trials were conducted in humans. Efficacy was highly variable
with many candidates demonstrating no protective effect,however,
there were some promising candidates identified that continue to
be further developed today (21), and these are discussed in more
detail below.
In the last decade, there has been an attempt to assist and accel-
erate development of a malaria vaccine with the establishment
of the PATH Malaria Vaccine Initiative (MVI), which has greatly
progressed the evaluation and identification of promising malaria
vaccine candidates. To further focus and unite the global vaccine
effort, in 2006 the World Health Organization (WHO) launched
the first malaria vaccine technology roadmap with the landmark
goal:
By 2015, develop and license a first generation malaria vac-
cine that has a protective efficacy of more than 50% against
severe disease and death and lasts more than one year (29).
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Currently, a single vaccine candidate is on track to meet this
goal. Known as “RTS,S,” this vaccine is based on the repeat region
and T-cell epitopes of CSP. RTS,S is the subject of a large multi-
centre Phase 3 trial involving more than 15,000 children over 11
sites in sub-Saharan Africa. The full results of the trial have not yet
been published; however, after three doses, clinical malaria cases
during the first 18 months of follow-up decreased by an estimated
46% (severe disease by 36%) in children 5–17 months of age at
first vaccination, and 27% (severe disease by 15%) in infants aged
6–12 weeks of age at first vaccination (30), therefore, RTS,S effi-
cacy is approaching the above-mentioned WHO criteria for a first
generation malaria vaccine. As a result, this vaccine is likely to
be licensed in 2015 for use in young African children and could
lead to significant decreases in malaria morbidity and mortality in
this high-risk population. Despite this positive outlook, it is cau-
tioned that this vaccine is only partially protective against disease
and wanes over time. New, second-generation vaccines will need
to have major improvements in efficacy to meet the challenges
ahead (10).
Recognizing the changing epidemiology of malaria in the con-
text of a shrinking global malaria map and a shift in populations
most at risk of infection (5), as well as the need for vaccines
with higher efficacies than RTS,S if malaria elimination is to be
achieved, the goals of the Malaria Vaccine Technology Roadmap
were recently reset with two major objectives:
By 2030, license vaccines targeting P. falciparum and P.
vivax that encompass: (i) development of second-generation
malaria vaccines that provide a protective efficacy of more
than 75% against clinical (mild and severe) malaria . . . and
(ii) development of malaria vaccines that reduce transmission
of the parasite and thereby reduce the incidence of human
infection . . . (31).
To achieve these new goals, a better understanding of the minimal
requirements and mechanisms underlying development of immu-
nity against P. falciparum and P. vivax (10, 12) as well as knowledge
regarding the factors that influence transmission of both species,
will be essential. As the development of vaccines against P. vivax
is also a major goal, it will be important to consider the distinct
features of this species, which underscores the need to intensify
research efforts into this relatively neglected parasite.
APPROACHES TO MALARIA VACCINE DEVELOPMENT
Malaria parasites are complex eukaryotes comprised of many anti-
genic targets. It has been suggested that vaccines may need to be as
complex as the parasite itself (32) and therefore there has been con-
siderable interest in the whole parasite approach. As mentioned
above, irradiated live sporozoite vaccinations have shown great
success in clinical trials (27, 33, 34). Currently, different methods
are being used to attenuate sporozoite stages including chemical
and genetic modification, and these have been reviewed elsewhere
(35). However, there are some challenges to overcome in addition
to the technical difficulties and high costs associated with scaling
up production including the dose required to induce long-lasting
protective immunity, transport, and storage in the absence of a
reliable cold chain for distribution to at risk populations (36).
There is also a risk of reversion to virulence (12). Hence the
alternative subunit vaccine approach continues to be vigorously
evaluated (37). As indicated above, this involves individual recom-
binant parasite proteins administered as monovalent preparations
or combinations of multiple proteins together with different vec-
tors and adjuvants that enhance the immune response. As the
majority of clinical trials conducted to date have been based on
subunit vaccines, this rest of this review will focus on the develop-
ment of this class of malaria vaccines and the challenges associated
with this approach.
Several highly abundant parasite proteins were identified as
targets of natural immunity many years ago but in recent years
the list of possible candidates has expanded. These candidates
have been extensively validated in pre-clinical studies using differ-
ent approaches including the measurement of inhibitory antibody
responses in in vitro growth and invasion assays (short term culture
only for P. vivax) (18, 38–41) and by vaccinating animal models
followed by challenge infections (17, 18, 42–45). Subunit vaccines
have been or are being developed based on these advanced candi-
date antigens, which are expressed in almost every stage of the par-
asite lifecycle. They have been classified into one of three different
groups based on the target lifecycle stage (Figure 1) (46):
(i) pre-erythrocytic vaccines: these vaccines aim to prevent infec-
tion by targeting the infective stage, known as the sporozoite
(e.g., RTS,S). Alternatively, pre-erythrocytic vaccines can tar-
get antigens expressed by liver stage parasites to prevent the
emergence of merozoites into the bloodstream, the stage of
infection responsible for the clinical symptoms of malaria
infection (Figure 1). The risk associated with targeting sporo-
zoite antigens is that the antigen dose inoculated during a
natural infection is very low, with only a small number of
sporozoites injected by the vector (~20), and this may not
be sufficient to elicit an effective host immune response.
Additionally, only one sporozoite needs to escape the vaccine-
mediated immune response and invade liver cells for ~10,000
infectious merozoites to be produced, resulting in blood stage
infection and clinical disease (47).
(ii) blood stage vaccines: the vast majority of malaria vaccine can-
didates are designed to protect against the blood stage of
infection (Figure 1). Since all of the symptoms of malaria
occur during this stage, the majority of vaccines target-
ing antigens expressed during the blood stage are designed
primarily to prevent disease. One approach is to target mero-
zoite antigens to prevent red blood cell invasion and reduce
the density and prevalence of parasites in the infected host
(Figure 1). In principle, this reduction in parasite density
may also reduce the density of transmission forms, known
as gametocytes (i.e., the sexual stage of the parasite trans-
mitted from human to mosquito host) (Figure 1). In addi-
tion to preventing clinical disease, an effective blood stage
vaccine that reduces parasite density may therefore also
contribute to reducing malaria transmission (10, 46, 48).
Approaches are also being developed to target the major sur-
face protein expressed on the P. falciparum infected red blood
cell known as erythrocyte membrane protein 1 (PfEMP1).
PfEMP1 mediates adhesion to host cells, a mechanism that is
associated with severe malaria [reviewed by Hviid (49)].
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FIGURE 1 | Malaria vaccine candidate antigens are shown. All candidate
antigens for Plasmodium falciparum and Plasmodium vivax are superimposed
on the Plasmodium lifecycle, to indicate the category of malaria vaccine being
developed and the lifecycle stage targeted. Antigens indicated in bold are
those that are currently being evaluated in pre-clinical trials or have entered at
least Phase 1 clinical trials according to the WHO malaria vaccine rainbow
tables (50). The P. vivax latent stages known as “hyponozoites” are not
shown but these occur in the liver stage.
(iii) transmission-blocking vaccines: the aim of transmission-
blocking vaccines is to target antigens expressed during
lifecycle stages in the mosquito host (e.g., gametocyte or
oocyst antigens) (Figure 1). Although these vaccines would
not directly prevent infection or clinical disease, they would
greatly assist elimination efforts to prevent the onward
transmission of infections that may be imported into an
elimination zone (10, 46).
Development of a vaccine against P. falciparum is well advanced
with 31 promising antigens identified (Figure 1). Currently, 27
subunit candidates comprising different domains and alleles for
22 different antigens are being tested in pre-clinical or clinical tri-
als (50) (Figure 1; Table 1). However, the majority of candidates
tested in clinical trials so far have been based on different formu-
lations and regions of a handful of antigens identified many years
ago, including CSP (51), the liver stage antigen 1 (LSA1) (52),
thrombospondin-related antigen (TRAP, also known as sporo-
zoite surface protein 2, SSP2) (53–55), merozoite surface protein 1
(MSP1) (56), MSP2 (57), MSP3 (58), and apical membrane anti-
gen 1 (AMA1) (42, 59). As some of these antigens have shown
promising pre-clinical profiles yet limited efficacy in human tri-
als, they have been tested in many different formulations over
the years (21, 60). For example, the most advanced blood stage
antigens, AMA1 and MSP1, naturally induce protective immune
responses (61–63), demonstrated using in vitro inhibition assays
(64) and by vaccination of animal models (17, 18, 20, 65). However
in humans,only limited clinical efficacy has been observed (66,67).
Similarly, CSP, the major component of the RTS,S vaccine, is the
major surface antigen on the sporozoite surface, yet provides only
partial and short-lived protection against the blood stage symp-
toms of malaria following vaccination of human volunteers. It
does not protect against infection per se as would be expected by a
pre-erythrocytic vaccine and therefore the precise mechanism of
protection is not well understood (23, 68). These “historical” vac-
cine candidates are much further down the development pipeline
(21) than more recently identified candidates such as the inva-
sion ligands, the 175 kDa erythrocyte binding antigen (EBA175)
(69), reticulocyte binding homolog 5 (RH5) (70, 71), and P. vivax
Duffy binding protein (DBP) (72). In recent years, the var2csa
variant of PfEMP1, which is the major parasite ligand involved in
placental adhesion during pregnancy malaria (73); and the game-
tocyte antigens, Pfs25 and Pfs48/45 (74) representing promising
transmission-blocking targets, have also come to the forefront.
The elucidation of the complete parasite genome (75) has fur-
ther advanced vaccine development by enabling identification
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Table 1 | Diversity of malaria vaccine candidate antigens currently in clinical trials based on the WHO rainbow tables (50).














CSP Sporozoite C-terminal 3 13 604 (9–143) 71 (3–20) (2)
1 1 157 n.r. (13–34) (83)
1 1 100 57 (84)
3 17 1339 (9–336) 117 (1–40) (85)
Full length 2 7 485 n.r. (86)
STARP Sporozoite Full length 1 1* 134 (10–24) 24 (87)
TRAP Sporozoite N-terminal 2 3 100 (8–48) 84 (8–37) (2)
LSA1 Liver stage N-terminal 3 4 74 (10–22) 13 (3–7) (2)
GLURP Sporozoite/gametocyte Region 0 3 3 48 (9–11) 22 (2–9) (2)
Region 0 and 2 1 1 77 (R0); 79 (R2) n.r. (88)
AMA1 Merozoite Domain I 3 11 572 (8–162) 181 (6–68) (2)
1 1 193 (9–100) 139 (6–58) (89)
Full length 2 7 459 n.r. (86)
1 1 21 11 (90)
1 1 129 78 (91)
1 1 315 168 (92)
EBA175 Merozoite Region II 2 3 135 (30–48) 51 (15–23) (2)
MSP1 Merozoite MSP119 3 11 2237 (18–1368) 20 (1–15) (2)
1 1 136 12 (83)
1 1 61 (9–15) 5 (93)
1 1 300 19 (94)
Block 2 1 1 35 23 (95)
1 1 36 13 (96)
1 1 128 14 (97)
Full length 2 7 404 n.r. (86)
MSP2 Merozoite Blocks 2 and 3 2 3 392 (n.d) 275 (n.r.) (2)
Block 3 1 1 148 22 (97)
MSP3 Merozoite Repeat region 2 2 124 (75–86) 21 (9–12) (2)
MSP4 Merozoite Full length 2 4 142 (12–42) 47 (9–23) (2)
MSP3/6 Merozoite 1 2 117 (51–66) n.r. (81, 82)
Rh2 Merozoite Binding region 1 1 33 (15) n.r. (13) (98)
Rh4 Merozoite Binding region 1 1 23 (12) 9 (4) (99)
RH5 Merozoite Full length 3 6 227 (21–125) n.r. (100)
Pfs48/45 Gametocyte Full length 3 4 55 (9–15) 19 (2–8) (2)
Pfs28 Ookinete No population data available
Pfs25 Ookinete Full length 2 2 41 n.r. (101)
var2csa Trophozoite DBL3 2 3 124 (15–54) n.r. (102)
DBL3X 1 1 108 79 (103)
DBL5 1 2 70 n.r. (104)
var Trophozoite DBLalpha 3 4 29–42 (32) 140–666 (449)** (105)
SERA5 Trophozoite/schizont Exon II–IV 4 9 445 (39–80) 133 (3–44) (106)
PLASMODIUM VIVAX
CSP Pre-eryth Central repeat (CR) 2 2 168 (31–137) n.r. (13–25) (107, 108)
3 9 194 76 (5–23) (109)
1 1 84 23 (95)
DBP Merozoite Region II 2 8 675 (11–123) n.r. (9–73) (110)
3 9 707 (11–200) 150 (8–59) (111)
1 1 63 16 (112)
1 1 70 13 (113)
1 1 22 8 (114)
1 1 54 12 (115)
3 7 402 (9–122) 138 (7–56) (116)
*Also included a small number of strains from Brazil, Indonesia, Tanzania and Kenya.
**Predicted total number of var alleles is much higher: 232–7565 (3564).
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of scores of novel antigens. Subsequent antigenic credentialing
through functional studies (76), proteomic and immunological
screening (63,77–80),and population genetic analyses (81,82),has
resulted in prioritization of several of these promising candidates
for further development.
Research on potential P. vivax vaccine candidates lags far
behind that of P. falciparum. Currently, only two P. vivax vaccine
candidates (based on PvCSP and PvDBP) have shown promise
in pre-clinical studies and only one candidate has reached Phase
1a clinical trials (50) (Figure 1). If the new goals of the Malaria
Vaccine Technology Roadmap are to be realized, significantly
more resources need to be invested in identifying and validat-
ing promising P. vivax vaccine candidates for progression to
clinical trials.
PARASITE DIVERSITY: A MAJOR OBSTACLE TO MALARIA
VACCINE DEVELOPMENT
One often quoted explanation for the variable efficacy of subunit
malaria vaccine candidates is parasite genetic diversity (2, 9, 12,
37) and the strain-specific nature of immunity to diverse parasite
antigens (15, 117, 118). Theoretically, a malaria “strain” can be
defined as a parasite variant that is genetically distinct and induces
specific immune responses against one or more antigens (Box 1).
However, exactly what defines a Plasmodium strain is not fully
understood (119) because this definition becomes exceedingly
complex when the whole parasite is considered. In the context
of subunit vaccines, the term “strain” refers to the parasite iso-
late from which the vaccine antigen is derived, while the actual
genetic variant of that antigen is known as the “allele” or “hap-
lotype” (Box 1). The inclusion of only one allele in a subunit
vaccine formulation elicits responses only against similar, cross-
reactive alleles (the“serotype,” Box 1) and runs the risk of selection
for non-vaccine strains in the vaccinated host population, as dis-
cussed in detail below (22). Indeed, natural parasite populations
have large numbers of alleles or haplotypes for single copy anti-
gens, such as AMA1 and MSP1 (2, 11) (Table 1). However for
PfEMP1, which is encoded by as many as 60 different genes per
parasite genome, there are hundreds to thousands of distinct alle-
les even within local geographic areas <10 km2 (105). Extensive
parasite antigenic diversity explains the slow development of natu-
rally acquired immunity (120) with repeated exposure over several
years necessary to build up a large repertoire of antibodies to the
different serotypes circulating in an endemic area (14, 121). Given
the high diversity of the available vaccine candidates (Table 1), a
broadly effective malaria vaccine may need to be multivalent, com-
prising multiple alleles (or haplotypes) for a given polymorphic
antigen (12), much like the vaccine approaches used to successfully
combat other highly polymorphic pathogens such as influenza A
and human papillomavirus.
On the other hand, some Plasmodium antigens are relatively
conserved, such as RH5 (100), or have highly conserved functional
regions that vaccine-developers may be able to exploit such as
the AMA1 receptor-binding pocket (122, 123). Furthermore, anti-
bodies against major surface antigens cross-react with different
parasite strains including those from different geographic areas
suggesting that conserved epitopes exist (65, 124). It has therefore
been proposed that using a panel of peptides containing conserved
epitopes would be one approach to induce immune responses that
avoid dominant polymorphic epitopes (125).
An important priority in malaria vaccine development is there-
fore to not only confirm the diversity circulating in the target
parasite population but also to understand the contribution of
genetic (allelic/haplotypic) diversity to the antigenic (serotype)
diversity that is relevant to malaria vaccine design for each candi-
date antigen (48). Whilst there are indeed multiple diverse alleles
of many candidate antigens circulating within distinct popula-
tions, not all polymorphisms, will mediate antigenic escape, hence
these must be identified and targeted for vaccine design. However,
the relationship between allele and serotype has been dissected
for only one candidate, AMA1 (126). More rigorous investigation
of available candidates as well as the identification of novel rela-
tively conserved antigenic targets is therefore absolutely required
to develop a framework for selection and to prioritize antigens for
further development as vaccine candidates.
DIVERSITY-COVERING VACCINE APPROACHES
Although well established, the extreme diversity of leading can-
didate antigens has rarely been considered when developing and
testing candidate malaria vaccines [reviewed by Barry et al. (2)].
The majority of subunit vaccine candidates tested in clinical tri-
als have been monovalent. Moreover, all vaccine candidates have
been based on alleles from a handful of parasite isolates such as
3D7, FC27, FUP, and FVO for P. falciparum, and Sal1 for P. vivax,
that have been propagated for decades in vitro (or in primate
models for P. vivax), and poorly reflect the parasite strains circu-
lating in natural populations (2, 110, 127–129). As a result, many
malaria vaccine candidates do not adequately cover the diversity
observed in natural parasite populations and this could explain
the poor clinical efficacy observed in vaccine trials where effi-
cacy endpoints include infection with any strain (21, 66, 127).
A multivalent malaria vaccine comprised of multiple serotypes
may perform better as it would be designed to protect against a
wide range of parasite strains. However, for almost all malaria vac-
cine candidates, the polymorphisms that define the serotypes and
the number of alleles that should be incorporated into a malaria
vaccine to cover serotype diversity remain unknown.
Supporting the argument for a multivalent vaccine strategy,
vaccine candidates based on a single allele for specific antigens have
demonstrated more strongly protective responses when strain-
specific endpoints (i.e., infection with a strain carrying the vaccine
allele) have been measured as compared to standard endpoints
(i.e., infection with any strain). One of the most successful vaccine
trials conducted to date was that of the “Combination B” vaccine,
conducted in 120 Papua New Guinean children. This vaccine con-
tained only the 3D7 allele of MSP1, MSP2, and the ring-associated
erythrocyte antigen (RESA), however, it resulted in a 62% reduc-
tion in parasite density in vaccinated children compared to those
that received the placebo (22). MSP2 contains a central complex
tandem repeat region and many different alleles that vary in size,
however all alleles fall into two major families that form differ-
ent serotypes (3D7 and FC27 ) (130). Interestingly, at the time of
vaccination, the prevalence of the 3D7 -type alleles was between
23 and 50% within each of the treatment groups, which could
explain the high overall efficacy. Furthermore, vaccinees were less
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frequently infected and had a lower rate of clinical episodes associ-
ated with 3D7 -type parasites compared to the control group (22).
Similarly, volunteers from Mali vaccinated with FMP2.1, which
is based on the 3D7 allele of AMA1, had a much higher risk of
non-3D7 infections (64%) (131) than any infection (20%) based
on residues in the AMA1 cluster 1 loop (c1L) (66). The results
of these trials highlight the danger of vaccine-induced selection
pressure and its consequences for morbidity, and strongly argue
for developing vaccines covering major serotypes circulating in
natural parasite populations (9, 22, 127). The frequency of vac-
cine or vaccine-serotypes in the target parasite population is also
likely to be important for significant vaccine efficacy. The biva-
lent candidate, AMA1-C1 (containing 3D7 and FVO haplotypes)
has demonstrated a lack of protective efficacy against either of the
two vaccine alleles in a Phase 2b trial (92). However, this lack of
observed efficacy could be explained by a low frequency of these
alleles in the target parasite population and the small sample size,
with only 44 sequences analyzed for both the vaccine and control
groups combined. Even when the analysis of polymorphisms was
narrowed to the c1L cluster of polymorphisms, which have been
implicated in antigenic escape as the basis of AMA1 serotypes
(126), baseline vaccine-allele frequencies were <10% indicating
that much larger sample sizes would be required to observe any
shift in frequency after vaccination. No other multivalent vaccine
trial results are currently available, but several trials are ongoing
and the malaria vaccine community awaits the final results with
interest.
Multivalent combination vaccines tested in animal models have
shown promising and surprising results. Vaccination with combi-
nations of four highly diverse AMA1 alleles was shown to overcome
diversity by producing a broader inhibitory response compared
to single allele vaccination, thought to have occurred partly by
redirecting responses to conserved epitopes (65, 132). This phe-
nomenon, which is analogous to “original antigenic sin,” occurs
because abundant, strain-specific AMA1 epitopes vary and are
potentially replaced with each new infection, whereas the con-
served regions remain constant. Hence, high levels of exposure
to conserved epitopes with vaccination or repeated exposure dur-
ing natural infections may enhance the antibody response against
these regions.
Another approach to covering antigenic diversity has been to
assemble all available global sequence data for an antigen target
and to design a small number of synthetic protein constructs that
together cover most of the diversity observed. Phase 1a and 1b
trials have begun after promising pre-clinical results for a mul-
tivalent vaccine candidate (DiCo), consisting of fusion protein
chimeras comprising three synthetic AMA1 molecules covering
97% of the amino acid variability, and these have been shown to
elicit stronger antibody responses as a combination than alone
(133). This approach has been further evaluated in pre-clinical
studies together with a construct containing two allelic variants
of the C-terminal 19-kDa region of merozoite surface protein 1
(MSP119) fused to the DiCo construct, and again enhanced anti-
body responses were induced (134). Clinical trial results are not
yet available for the DiCo and MSP119-DiCo combination vac-
cines but it will be interesting to see whether the diversity-covering
approach is more efficacious than the single allele approach.
PREDICTING SEROTYPES THROUGH POPULATION GENETIC
ANALYSES
Population genetic studies are needed to guide vaccine design, by
defining the diversity of candidate antigens, to predict polymor-
phisms that contribute to antigenic diversity (122, 127, 135) and to
investigate the geospatial distribution of predicted serotypes (136,
137). Moreover, as a continuous in vitro culture system is yet to
be developed for P. vivax, epidemiological studies currently repre-
sent an important tool with which to investigate the significance
of polymorphism within vaccine candidate antigens (125). This
approach has been used to identify correlations between specific
polymorphic sites in two leading P. falciparum vaccine candidates,
MSP1 and AMA1, with clinical infection (127, 138).
The extensive genetic diversity of malaria vaccine candidate
antigens has been demonstrated by many studies investigating
genetic polymorphism in samples ranging from small numbers
of geographically disparate culture-adapted isolates to large num-
bers of natural parasite isolates from the same local geographic
area or country. These results demonstrate the high numbers of
haplotypes found in natural parasite populations for many anti-
gens (Table 1). However, there are fewer haplotypes and vaccine
alleles are far more common when individual amino acid poly-
morphisms or limited “haplotypes” (Box 1) comprising different
combinations of amino acid alleles that might form critical epi-
topes are considered. For example, AMA1, which has 214 amino
acid haplotypes in 1 African population, has only 25 serotypes
based on the c1L cluster (127), demonstrating that if the haplotype
can be refined to represent only antigenic escape polymorphisms,
the number of alleles required in a potential multivalent vac-
cine could be reduced substantially. More recent studies have
suggested that the majority of the antigenic escape diversity in
AMA1 may even be explained by polymorphism in just one residue
(130). Importantly, in vaccine trials, a lack of knowledge of the
polymorphisms that mediate antigenic escape would result in
an underestimate of strain-specific vaccine efficacy. Population
genetic studies are therefore critical to gain more insight into anti-
genic diversity and to achieve the goal of a broadly efficacious
malaria vaccine.
Another important point to remember is that the global P. falci-
parum and P. vivax populations are structured into geographically
distinct subpopulations, therefore, local population-level analyses
are required to fully understand diversity that would be relevant
to the efficacy of a malaria vaccine in a defined endemic area
(139, 140). Given the large number of parasite populations that are
likely to exist worldwide it may not be feasible to design vaccines
for every target population and therefore a universal approach to
cover diversity is needed. Below, we provide a step-by-step guide of
how to identify and characterize diversity within candidate anti-
gens that is relevant to malaria vaccine design, and this is further
summarized in Figure 2.
DATA COLLECTION
In order to understand the antigenic diversity impacting on vac-
cine efficacy and to identify potential serotypes, the target gene
or gene region encoding the candidate antigen must be amplified,
sequenced, and population genetic analyses completed including
the determination of regions under balancing (immune) selection.
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FIGURE 2 | Understanding diversity and predicting serotypes using population genetic analyses. A flow chart describing the step-by-step methodology
to define the extent and distribution of parasite diversity and to predict antigenic escape polymorphisms and serotypes (see text for more details).
To accurately estimate natural allele frequencies, it is critical to
collect sequence data from samples representing the natural par-
asite population of a defined geographic area. Use of samples
collected in the same geographic area ensures that the diversity
of the target sequence is accurately estimated for that region. As
the most informative analyses of balancing selection are based
on allele frequencies, it is also important that sequence data are
obtained from a substantial dataset, at least 30–50 samples (81, 82).
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Analysis of too few sequences can result in incorrect estimates of
diversity, as alleles might be under-represented in very small pop-
ulation samples, and this can result in skewed allele frequencies
and diversity estimates.
Prior to PCR amplification, it is essential that parasite isolates
are genotyped using highly polymorphic microsatellite mark-
ers to determine the number of distinct parasite clones present
in the sample (141, 142). Even samples collected from areas of
low malaria transmission can contain multiple clones, especially
for P. vivax with its frequent relapses (143). If only one clone
is present, sequencing can be performed directly from ampli-
cons. If the number of field samples containing a single clone
is insufficient, or polyclonal infections are common, PCR prod-
ucts amplified from polyclonal samples can be sub-cloned prior to
sequencing. However, sub-cloning often results in artifacts (144),
therefore, any novel polymorphisms should be resolved by cloning
and sequencing-independent PCR products. Another approach is
to perform NextGen sequencing on samples containing multiple
clones, once a prohibitively expensive approach that is becoming
increasingly affordable. Briefly, amplicons are sheared and adap-
tors added, generating a library for each sample. Libraries can be
sequenced separately or as pools with the addition of sample bar-
codes. Reads are subsequently mapped to the relevant reference
genome. The advantage of this approach is that reads are quan-
titative and relate to clone abundance in the sample, therefore,
haplotypes of the predominant clone(s) can be computationally
reconstructed (145).
IDENTIFICATION OF POLYMORPHISM
From the raw sequence data, consensus sequences can be obtained
and compared to the reference sequence for the defined candidate.
Polymorphisms identified in consensus sequences will form the
basis of all downstream population genetic analyses. Quality con-
trol of sequences is therefore essential, to ensure that polymorphic
sites are accurately called and that any ambiguous sites or arti-
facts are identified. If a clear result cannot be obtained, the sample
should be removed from the analysis.
At this point, all high quality consensus sequences from a
given population can be compared and basic diversity parameters
determined as outlined below. In order to place the dataset in
context with the known diversity, published sequences of the tar-
get region collected from other natural populations in distinct
geographical areas can also be added to the analysis (e.g., from
GenBank). Multiple alignments of sequence data are straightfor-
ward if sequences are non-repetitive. However, if repeat length
polymorphisms, which are common in parasite antigens, or inser-
tions and deletion (indels) are found, then manual realignment
needs to be done to ensure that gaps are correctly aligned, which
can lead to an overestimate of the number of single nucleotide
polymorphisms (SNPs). While repeat regions can be included
in population genetic analyses, the expansion and contraction of
repeat arrays does not impact on antigenic diversity as dramatically
as amino acid changes (22, 131). However, by defining different
alleles based on the number of repeats or in the case of indels,
the presence or absence of a particular string of nucleotides, it is
possible to predict whether such polymorphisms are modulated
by immune selection.
Balancing selection, which is a result of immune selection pres-
sure, favors the maintenance of diversity, with alleles at low to
medium frequencies within populations, and balanced frequen-
cies between populations (137). Polymorphic sites or regions that
show such patterns are predicted to be under the influence of
immune selection, and thus contribute to antigenic diversity. For
some antigens under strong immune selection, similar alleles or
clusters of alleles have been maintained across broad geographic
areas (2, 110, 127, 129, 136, 146). The maintenance of moderate
frequencies of allele clusters (and even individual alleles) across
large geographic distances indicates that they represent distinct
serotypes (2, 146).
In contrast, singleton polymorphisms and polymorphic sites
with very low minor allele frequencies (MAFs) are indicative of
deleterious mutations under purifying selection, or recent poly-
morphisms yet to increase in frequency. These polymorphisms
will only be represented in a very small proportion of the par-
asite population. As the aim of diversity-covering vaccines is to
encompass as many of the alleles (haplotypes) found as possible,
several groups have chosen to exclude rare polymorphisms from
population genetic analyses of vaccine antigens (110, 129, 145).
Another cautionary note is that a large number of singleton poly-
morphisms in population datasets from the public databases may
also indicate PCR artifacts, especially if the methodology includes
a cloning step. If the validity of such data cannot be confirmed
then it should be discarded from the comparative analyses.
ANALYSIS OF THE EXTENT AND DISTRIBUTION OF DIVERSITY
In order to determine the diversity of the candidate antigen, both
overall and within parasite populations from different geographic
areas (e.g., village, district or country), genetic diversity should
be estimated for all sequences combined and for each popula-
tion. Genetic differentiation (e.g., Wrights fixation index, F ST)
can be measured to determine whether allele frequencies vary
and if not, populations from the same region or country can
be considered as one population (2). Important diversity para-
meters to define for each population include the number and
type of polymorphisms (SNP, indel, repeat length variation), the
number and relative proportions of neutral (synonymous) and
amino acid (non-synonymous) polymorphisms, and the num-
ber of haplotypes resulting from different combinations of amino
acid polymorphisms. All of these statistics can be calculated
using freely available population genetic analysis software and an
excellent overview of these programs has been published (147).
Conversion of polymorphisms to amino acid residues before hap-
lotype definition ensures that complex codons and rare nucleotide
polymorphisms within codons containing other more common
polymorphisms are included. In any case, it is more appropri-
ate to describe the amino acid haplotypes to predict serotypes,
rather than the nucleotide haplotypes. Other more complex sta-
tistics such as the nucleotide and haplotype diversity can also
be measured as an indication of the number and frequency of
polymorphisms and haplotypes in the population, respectively;
however, these are of more interest to the population geneticist
than the vaccine developer.
To determine whether polymorphic sites are under the influ-
ence of balancing (immune) selection, statistical tests such as

























































Barry and Arnott Overcoming antigenic diversity for malaria vaccines
Tajima’s D can be performed using a sliding window approach, to
identify specific domains or clusters of polymorphisms targeted by
host immune responses (148). In addition, Wright’s F ST, has been
applied to investigate whether allele frequencies at specific poly-
morphic sites, or gene domains, are balanced between populations
(137). Polymorphisms under balancing selection and associated
with immune escape will be non-synonymous, located in regions
with a positive value of Tajima’s D and low inter-population F ST
values. However, sampling is extremely important as both the
Tajima’s D and F ST tests are based on allele frequencies. Popu-
lations must be of sufficient size so that the sampling error of the
estimate is low, and panmictic (randomly mating) from the same
geographic region, because any underlying geographic population
structure may influence antigen allele frequencies (129, 136, 139,
140). Polymorphisms under balancing selection are also likely to
have moderate MAFs, because the maintenance of diversity in the
parasite population is advantageous for survival (137). The phys-
ical location of all polymorphisms identified as immune targets
should then be mapped to the protein structure where possible,
to help determine the potential functional relevance and implica-
tions of mutation at the site(s) identified, as has been successfully
done for AMA1 [e.g., Ref. (126, 127)].
Determining the extent and distribution of immunologically
relevant diversity for potential malaria vaccine candidates will help
to determine the feasibility of whether a regionally or globally
effective vaccine can be developed for the particular target. It is
therefore important to focus the analysis to only those polymor-
phisms with the greatest likelihood of creating antigenic diversity
to allow immune escape. Once polymorphisms predicted to be
under balancing selection have been identified (see above and
Figure 2), the distribution of unique haplotypes representing the
predicted serotypes can be analyzed by determining haplotype
frequencies in different geographic areas.
Different haplotypes will be related to differing degrees. Using
network and clustering analyses, relationships between haplotypes
from different populations, clusters of closely related haplotypes,
and the extent and distribution of predicted serotypes can be inves-
tigated. By identifying the relationships among all of the different
haplotypes in this way, the most distantly related alleles can be
selected for further analysis or for inclusion in a vaccine to cover
diversity. Previous studies have demonstrated the utility of these
approaches to identify distinct clusters of alleles as a starting point
to predict serotypes (11, 146, 149). These analyses identify the
most distinct and common haplotypes and provide a basis upon
which to select haplotypes that cover a large proportion of the
population-wide diversity for a specific candidate antigen. The
outcome of such analyses can help to determine: (i) whether it
may be possible to cover all known diversity of the target sequence,
(ii) the number of different haplotypes that would need to be
included in a vaccine in order to cover diversity and (iii) the pre-
dicted efficacy of vaccine candidates. Inclusion of vaccine alleles in
the analysis provides a reference point to estimate vaccine allele or
serotype frequencies. The results of these analyses provide a simple
diversity framework upon which to determine the parameters of
allele specific and cross-reactive responses in pre-clinical studies
(65, 127, 146) and to measure strain-specific efficacy in clinical
trials (131). It is important to note that unlike other approaches
that have clearly identified antigenic escape polymorphisms (126,
131), population genetic analyses provide a prediction, are simpler
and less expensive, and can reduce the number of polymorphisms
(and thus haplotypes) that need to be assessed to confirm their
contribution to the serotype.
DEFINING ANTIGENIC DIVERSITY BY MONITORING THE
DYNAMICS OF DIVERSITY IN NATURAL PARASITE
POPULATIONS
Children living in malaria endemic areas are infected many times
and have several episodes of clinical malaria before building up
a large repertoire of antibodies that recognize a large number
of strains (14, 15). Meanwhile, the rate of turnover of infections
increases with age and is thought to be associated with the acqui-
sition of antibodies to an increasing breadth of strains (150).
Therefore, strains that children are yet to be exposed to pose
a greater risk of clinical illness. Defining the dynamics of clin-
ical infection in the context of parasite antigenic diversity may
therefore provide insights into the specific genetic determinants
required for antigenic escape, since the risk of a clinical episode
due to infection with parasites representing a specific serotype
would decrease after being exposed to that serotype (Figure 3A)
(127, 138). Furthermore, analyses of strain-specific antibodies in
conjunction with such analyses would confirm the status of immu-
nity at a particular time point and allow associations to be made
between gaps in the antibody repertoire and risk of a clinical
episode (62, 98, 99, 151). Longitudinal studies in endemic regions
that monitor children at regular time intervals for the presence
of specific antibodies or the turnover of alleles at antigen loci
could therefore be harnessed to identify the genetic determinants
of antigenic diversity.
MEASURING STRAIN-SPECIFIC EFFICACY IN VACCINE
TRIALS
Vaccines based on a single allele of the candidate antigen elicit
strain-specific antibodies, so that vaccinated individuals continue
to be at risk of infection with different strains but risk of infec-
tion with the vaccine strain is lower (Figure 3B) (22, 66, 131).
Vaccine trials with strain-specific endpoints (i.e., infection with a
particular parasite genotype) therefore represent a major oppor-
tunity to characterize the genetic determinants responsible for
immune escape; however, this has been rarely attempted. Given
the high diversity of most malaria vaccine candidates and the lim-
ited efficacy of single-strain vaccine candidates, for any candidate
that elicits strain-specific responses it will be essential to mea-
sure strain-specific endpoints to ensure that antigenic escape is
explored in vaccine testing. The advent of high throughput geno-
typing approaches (142, 152) has reduced the effort and funding
required for molecular epidemiological studies, and therefore as
long as relevant expertise is available, these investigations should
be relatively simple to incorporate into a vaccine trial.
The primary efficacy endpoint in clinical trials of malaria vac-
cines has included a range of measurements such as time to first
infection, occurrence of a clinical episode (mild and severe), and
parasite density. However, only a few malaria vaccine trials have
determined whether efficacy against vaccine or closely related
strains has been achieved (22, 92, 131). Below, we cover some
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FIGURE 3 | Antigenic diversity, clinical malaria, and vaccine efficacy are
shown. Simplified overview of the impact of parasite antigenic diversity on
the dynamics of natural infection and the efficacy of vaccines. Peaks in
parasitemia correspond with different clinical episodes and colors indicate
different serotypes. Strain-specific acquired antibodies are shown in
corresponding colors some time after each clinical episode. Solid lines
represent a strong antibody response, while dashed lines represent limited
antibody responses. (A) Dynamics of natural infection with recurrent
episodes of clinical malaria in an individual that acquires only strain-specific
antibodies after being infected. As individuals experience different strains
through natural infection (or vaccination), they acquire strain-specific
antibodies and have a lower risk of having a clinical episode due to the
same strain. (B) Lack of vaccine efficacy in a vaccinated individual due to
antigenic diversity. The syringe indicates vaccination with a single serotype
(red). If a single-strain vaccine is given at baseline, individuals are more
likely to experience clinical episodes due to other strains (blue, yellow,
green) than the vaccine strain, until antibody responses decrease.
molecular epidemiological analyses that could be considered in
the different stages of a vaccine trial.
VACCINE TRIAL RECONNAISSANCE
The low prevalence of vaccine alleles within natural populations
has been proposed to limit vaccine efficacy (2, 11, 129, 138).
Furthermore, a low prevalence of the vaccine allele will make it
extremely difficult to measure allele specific efficacy, since changes
may be very small and therefore require exceedingly large sam-
ple sizes (92). Therefore, even before a vaccine trial begins in
a particular geographic area, molecular epidemiological surveys
will be important to assess baseline population genetic charac-
teristics, and in particular the allele- (or if known, the serotype-)
frequencies to ensure that the vaccine to be tested is representative
of the target parasite population.
STRAIN-SPECIFIC ENDPOINTS
In addition to measuring strain-specific endpoints by determin-
ing the time to first clinical episode with vaccine and non-vaccine
alleles, the analysis of outcomes in control and vaccine groups pro-
vide an opportunity for more detailed analyses that can provide
key insights into the complexities of parasite antigenic diversity
(92, 127, 153). In principle, the same analyses can be done in
longitudinal studies to achieve the same goal. These analyses will
provide further functional evidence of antigenic escape polymor-
phisms, thus allowing refinement of the serotype. Different types
of analyses that have been used to measure strain-specific efficacy
in vaccine trials include:
(i) measuring strain-specific protection by assessing risk of clinical
episode associated with parasites carrying the vaccine-allele
compared to those carrying any non-vaccine allele;
(ii) measuring cross-strain protection by assessing risk of clinical
infection with parasites carrying the vaccine-allele compared
to those carrying different non-vaccine alleles;
(iii) measuring vaccine-mediated selection by:
a. comparison of allele or haplotype frequencies before and
after vaccination in the different vaccine groups;
b. comparison of the incidence of infection with parasites
carrying different haplotypes and individual polymor-
phisms before and after vaccination;
(iv) assessment of vaccine-mediated strain-specific natural immu-
nity by measuring antibodies to vaccine alleles in vaccine and
control groups.
VACCINE-MEDIATED SELECTION AND ANTIGENIC ESCAPE MUTANTS
The development and licensing of an effective malaria vaccine
will require sustained and intensive surveillance to monitor for
vaccine-mediated selection of non-vaccine alleles and to ensure
that vaccine alleles are common enough for vaccines to remain
effective. Regular population genetic surveys will be required in
order to monitor allele frequencies, to ensure that alleles contained
within the vaccine continue to represent the diversity of the par-
asite population and that new, potential antigenic escape mutants
have not emerged. A genetic surveillance system would be difficult
and costly to implement, but the development of low cost rapid
assays to quickly genotype parasite isolates would facilitate such
an approach (152). The need for simple and informative surveil-
lance tools also highlights the importance of gaining knowledge
into the precise determinants of antigenic diversity in any antigen
to be included in a licensed malaria vaccine.
CONCLUSION
The trials and tribulations of malaria vaccine development have
reached a critical juncture. The first licensed malaria vaccine is
almost at hand and children in African countries stand to benefit
greatly from its availability. However, this vaccine is only partially
effective against the symptoms of malaria, not infection, and pro-
vides only short-lived protection (23). As a result of the success of
the reinvigorated global malaria eradication program, many pre-
viously highly endemic countries no longer have high burdens of
disease. By 2030, the goal is to have a second-generation vaccine(s)
that can provide broad and long-lived protection against multi-
ple species and diverse strains. Parasite antigenic diversity, one of
the major reasons for the failures of past candidate malaria vac-
cines, remains a barrier to the efficacy of subunit and potentially
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even whole parasite vaccine approaches (48), but there is light at
the end of the tunnel: this review demonstrates how it may be
possible to overcome parasite antigenic diversity. Successful iden-
tification of the critical genetic determinants of the serotype for
one leading vaccine candidate, AMA1 (126, 127, 131) and proof
that multivalent vaccines representing the majority of the diversity
of this antigen can generate broad antibody responses further sup-
port the development of effective multi-allele vaccines and suggest
that antigenic diversity in malaria may be overcome (65, 132). By
consolidating the vast knowledge gained on the genetic diversity
of candidate antigens, by harnessing high throughput genotyping
tools and with careful design of longitudinal studies and vaccine
trials, it is highly likely that it will also be possible to identify the
critical genetic determinants underlying antigenic diversity (i.e.,
the serotype) for any candidate malaria vaccine antigen.
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